← Compound index
RESEARCH FAMILY / BESTIM

BestimБестим

A synthetic dipeptide with a gamma peptide bond between D-glutamate and L-tryptophan (γ-D-Glu–L-Trp). Studies examined immune-cell binding and its use alongside standard treatment.

Immune Function
Source linked

What the studies found

Observational study · 2018

[Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia].

Affective-asthenic subgroup
32.5%
Asthenic-negative subgroup
67.5%
Later symptom regression in asthenic-negative subgroup
More marked in the authors’ comparisonp<0.001

Adjunctive Bestim was associated with reduced asthenic symptom scores during complex psychiatric treatment.

Study notes · methods, sources and limitations

Participants or model 43 men aged 20–55 with schizophrenia and asthenic symptoms

Design 43 men aged 20–55 with schizophrenia and asthenia; clinical assessments before treatment and 5/30 days afterward.

Important limitations

  • An untreated concurrent control and random allocation are not established by the abstract; improvement cannot be attributed to Bestim alone. Full methods, reporting completeness and independent replication remain to be appraised.
  • The percentages describe symptom categories, not responder rates.

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 29652309 · Original journal report

Original source or citation ↗

Study results and tables ↗

Observational study · 2004

[Impact of Bestim on the immunological status and clinical course of ulcer].

The report describes immune-marker changes, symptom regression and ulcer scarring with adjunctive Bestim.

Study notes · methods, sources and limitations

Participants or model Patients receiving combined antiulcer treatment; sample size absent from abstract

Important limitations

  • Sample size, comparator details and quantitative effects require the full report; this is not reliable evidence of standalone efficacy. Full methods, reporting completeness and independent replication remain to be appraised.

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 16259438 · Original journal report

Original source or citation ↗

Study results and tables ↗

Lab research · 2008

Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes

Study of multiple preparations

Bestim binding Kd, intact macrophages/thymocytes
2.1 ± 0.1 / 3.1 ± 0.2 nM
Bestim binding Kd, isolated membranes
18.6 ± 0.2 / 16.7 ± 0.3 nM
Thymogen competition Ki
0.9 ± 0.1 / 1.1 ± 0.1 nM

Radiolabeled gamma-D-Glu-L-Trp bound mouse immune cells; unlabeled Thymogen competed for binding. This supports a shared binding interaction under assay conditions, not equivalent immunological outcomes in people.

More reported outcomes
Bestim adenylate-cyclase inhibition range
10⁻¹⁰–10⁻⁶ M
Study notes · methods, sources and limitations

Participants or model Murine macrophages, thymocytes and isolated membranes

Design Radiolabeled Bestim binding to mouse macrophages/thymocytes and isolated membranes; tracer activity 45 Ci/mmol.

Important limitations

  • Cell-binding experiment, not a clinical trial. Preserve gamma linkage and D/L stereochemistry; generic database synonyms may be misleading.
  • Binding affinities are not clinical dose equivalences. The Ki row concerns Thymogen competition, not Bestim Kd.

Primary source linked above · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Bestim

Names in this research collection

gamma-D-Glu-L-Trp · γ-D-Glu-L-Trp

Research background

A gamma-linked D-Glu/L-Trp dipeptide with immune-cell binding research and limited human adjunct-treatment reports. Distinct from Thymogen and Thymodepressin.

Autoimmune research: disease-specific findings, immune effects and open questions ↗

Compound class
Peptide research family
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

43 men aged 20–55 with schizophrenia and asthenic symptoms

Study methods

Study records describe the tested models, comparators and reported outcomes.

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history
IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Research objects, findings and source boundaries
MemberIdentityWhat the source supports
Bestimγ-D-Glu-L-Trp

Human reports cover 43 men with schizophrenia and adjunct anti-ulcer treatment. Concurrent treatment and incomplete design reporting prevent an isolated efficacy conclusion.

Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes ↗

[Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia]. ↗

[Impact of Bestim on the immunological status and clinical course of ulcer]. ↗

Thymogen comparatorL-Glu-L-Trp

Competed in the binding assay; no equivalence of clinical effects follows.

Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes ↗

Interpretation and open questions

Changes in linkage and stereochemistry yield distinct molecules. Database names alone do not resolve their structures.

Human reports supplement the binding studies; full allocation, harms and concurrent-treatment details still need appraisal.

Explore the Russian peptide research map ↗

What remains unclear

The psychiatric and ulcer reports leave allocation, concurrent treatment and adverse events unclear. The studies cannot isolate the effect of Bestim.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2018 · RU2672861C2 · Gamma-D-Glu-L-Trp: interferon combination claimFormulation · Initial improvement followed by worsening the next day; no complaints by day 5

Findings described in words

Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.

Pharyngitis example
Initial improvement followed by worsening the next day; no complaints by day 5One 27-year-old patient; the transient worsening is retained
Respiratory-illness example
Nasal discharge reportedly stopped and general condition improved by day 3Individual case; natural recovery and concurrent effects are not separated
All reported results, comparisons and limitations →

Formulation. The later patent explicitly names gamma-D-glutamyl-L-tryptophan in combination with type I or III interferon.

This is a combination claim rather than a patent on standalone Bestim efficacy; it does not resolve the older L/L-versus-D/L naming conflict.

Publication
RU2672861C2 ↗ · 2018-11-20
Earliest priority / filing
2014-10-31 / 2014-10-31
Original applicant / assignee
Общество с ограниченной ответственностью "Эксифарм" (ООО "Эксифарм")
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
56095723 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Composition based on interferon i or iii type and gamma-d-glutaminyl-l-tryptophan for prevention and treatment of infectious diseases and immunodeficiency conditions (options)

Inventors: Евгения Валерьевна Безрукова; Илья Владимирович Духовлинов; Александр Митрофанович Ищенко; Александр Леонидович Кадыков; Александр Александрович Колобов; Александр Владимирович Петров; Андрей Семенович Симбирцев.

RU2672861C2

Original patent PDF ↗

Read source review →

1998 · RU2120298C1 · Bestim: historical stereochemistry conflictIdentity unresolved · Total and T-lymphocyte measures described as returning to normal; patient discharged in satisfactory condition

Findings described in words

The patent reports restoration of lymphocyte measures in a selected case, with no controlled clinical effect estimate.

Post-thymectomy case
Total and T-lymphocyte measures described as returning to normal; patient discharged in satisfactory conditionSingle 18-year-old patient; image-based numerical table not transcribed
Other selected case
Colon-cancer-associated immunodeficiency example describedNo verified group response rate or independently extracted effect size
All reported results, comparisons and limitations →

Identity unresolved. This historical patent calls its agent Bestim but claim 1 specifies gamma-L-Glu-L-Trp. The current research card describes gamma-D-Glu-L-Trp.

These stereoisomers cannot be treated as identical. The name alone does not establish continuity between the patent, later literature and current products.

Publication
RU2120298C1 ↗ · 1998-10-20
Earliest priority / filing
1995-11-28 / 1995-11-28
Original applicant / assignee
Товарищество с ограниченной ответственностью "Верта"; Товарищество с ограниченной ответственностью "Цитокин"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20174019 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Immunostimulating agent and a preparation based on thereof

Inventors: О.А. Кауров; С.А. Кетлинский; А.А. Колобов; А.С. Симбирцев.

RU2120298C1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2018

Gamma-D-Glu-L-Trp: interferon combination claim — RU2672861C2

Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.

Pharyngitis example · Initial improvement followed by worsening the next day; no complaints by day 5 · One 27-year-old patient; the transient worsening is retained

Study notes and original source
2018Patent / reported experimentsFull text available

Gamma-D-Glu-L-Trp: interferon combination claim — RU2672861C2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Евгения Валерьевна Безрукова, Илья Владимирович Духовлинов, Александр Митрофанович Ищенко, Александр Леонидович Кадыков, Александр Александрович Колобов, Александр Владимирович Петров, Андрей Семенович Симбирцев · RU2672861C2 · patent family 56095723

Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.

Results and tables

Reported patent results

Findings described in words

Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.

Selected clinical examples of gamma-D-Glu-L-Trp plus interferon; the observations concern a combination, not standalone Bestim.

Population or model Selected clinical examples of gamma-D-Glu-L-Trp plus interferon; the observations concern a combination, not standalone Bestim.

Results · Clinical Examples 6–7; combination identity and individual clinical course.
MeasureResultComparison, timing and statistics
Pharyngitis exampleInitial improvement followed by worsening the next day; no complaints by day 5One 27-year-old patient; the transient worsening is retained
Respiratory-illness exampleNasal discharge reportedly stopped and general condition improved by day 3Individual case; natural recovery and concurrent effects are not separated

Uncontrolled short-duration cases do not establish superiority to either component. The D/L molecule must remain distinct from the older L/L Bestim patent.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Selected clinical examples of gamma-D-Glu-L-Trp plus interferon; the observations concern a combination, not standalone Bestim.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • This is a combination claim rather than a patent on standalone Bestim efficacy; it does not resolve the older L/L-versus-D/L naming conflict.
  • Uncontrolled short-duration cases do not establish superiority to either component. The D/L molecule must remain distinct from the older L/L Bestim patent.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 1998

Bestim: historical stereochemistry conflict — RU2120298C1

The patent reports restoration of lymphocyte measures in a selected case, with no controlled clinical effect estimate.

Study notes and original source
1998Patent / reported experimentsFull text available

Bestim: historical stereochemistry conflict — RU2120298C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

О.А. Кауров, С.А. Кетлинский, А.А. Колобов, А.С. Симбирцев · RU2120298C1 · patent family 20174019

The patent reports restoration of lymphocyte measures in a selected case, with no controlled clinical effect estimate.

Results and tables

Reported patent results

Findings described in words

The patent reports restoration of lymphocyte measures in a selected case, with no controlled clinical effect estimate.

Historical Bestim patent describes gamma-L-Glu-L-Trp and selected immunodeficiency cases, including a patient after thymus removal.

Population or model Historical Bestim patent describes gamma-L-Glu-L-Trp and selected immunodeficiency cases, including a patient after thymus removal.

Results · Description: clinical case examples and Table 5 narrative; stereochemical identity retained.
MeasureResultComparison, timing and statistics
Post-thymectomy caseTotal and T-lymphocyte measures described as returning to normal; patient discharged in satisfactory conditionSingle 18-year-old patient; image-based numerical table not transcribed
Other selected caseColon-cancer-associated immunodeficiency example describedNo verified group response rate or independently extracted effect size

This L/L patent molecule differs from the D/L sequence on the current Bestim research card. Name similarity cannot transfer the clinical observation to a different stereoisomer.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Historical Bestim patent describes gamma-L-Glu-L-Trp and selected immunodeficiency cases, including a patient after thymus removal.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • These stereoisomers cannot be treated as identical. The name alone does not establish continuity between the patent, later literature and current products.
  • This L/L patent molecule differs from the D/L sequence on the current Bestim research card. Name similarity cannot transfer the clinical observation to a different stereoisomer.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Observational study · 2018

[Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia].

Adjunctive Bestim was associated with reduced asthenic symptom scores during complex psychiatric treatment.

Affective-asthenic subgroup · 32.5%

Study notes and original source
2018Uncontrolled human reportEnglish abstract

[Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia].

· Original journal report

Yakimets AV, Zozulya SA, Oleichik IV, Klyushnik TP · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 29652309

Adjunctive Bestim was associated with reduced asthenic symptom scores during complex psychiatric treatment.

Results and tables

Reported findings and study design

43 men aged 20–55 with schizophrenia and asthenia; clinical assessments before treatment and 5/30 days afterward.

Population or model 43 men aged 20–55 with schizophrenia and asthenic symptoms

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Affective-asthenic subgroup32.5%
Asthenic-negative subgroup67.5%
Later symptom regression in asthenic-negative subgroupMore marked in the authors’ comparisonp<0.001

The percentages describe symptom categories, not responder rates.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
43 men aged 20–55 with schizophrenia and asthenic symptoms
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • An untreated concurrent control and random allocation are not established by the abstract; improvement cannot be attributed to Bestim alone.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-10-05.

Read the source ↗

Observational study · 2004

[Impact of Bestim on the immunological status and clinical course of ulcer].

The report describes immune-marker changes, symptom regression and ulcer scarring with adjunctive Bestim.

Study notes and original source
2004Uncontrolled human reportEnglish abstract

[Impact of Bestim on the immunological status and clinical course of ulcer].

· Original journal report

Tkacheva AG, Kalev OF, Dolgushina AI, Antipina TV · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 16259438

The report describes immune-marker changes, symptom regression and ulcer scarring with adjunctive Bestim.

Population / setting
Patients receiving combined antiulcer treatment; sample size absent from abstract
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • Sample size, comparator details and quantitative effects require the full report; this is not reliable evidence of standalone efficacy.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-10-05.

Read the source ↗

Lab research · 2008

Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes

Radiolabeled gamma-D-Glu-L-Trp bound mouse immune cells; unlabeled Thymogen competed for binding. This supports a shared binding interaction under assay conditions, not equivalent immunological outcomes in people.

Study notes and original source
2008In vitroEnglish abstract

Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes

· Primary source linked above

Radiolabeled gamma-D-Glu-L-Trp bound mouse immune cells; unlabeled Thymogen competed for binding. This supports a shared binding interaction under assay conditions, not equivalent immunological outcomes in people.

Results and tables

Reported findings and study design

Radiolabeled Bestim binding to mouse macrophages/thymocytes and isolated membranes; tracer activity 45 Ci/mmol.

Population or model Murine macrophages, thymocytes and isolated membranes

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Bestim binding Kd, intact macrophages/thymocytes2.1 ± 0.1 / 3.1 ± 0.2 nM
Bestim binding Kd, isolated membranes18.6 ± 0.2 / 16.7 ± 0.3 nM
Thymogen competition Ki0.9 ± 0.1 / 1.1 ± 0.1 nM
Bestim adenylate-cyclase inhibition range10⁻¹⁰–10⁻⁶ M

Binding affinities are not clinical dose equivalences. The Ki row concerns Thymogen competition, not Bestim Kd.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Murine macrophages, thymocytes and isolated membranes
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Cell-binding experiment, not a clinical trial.
  • Preserve gamma linkage and D/L stereochemistry; generic database synonyms may be misleading.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗